Fitbit Inc., the US-based wearable technology device manufacturer, headquartered in San Francisco, CA, had been developing a method to detect irregular heart rhythms by forming a partnership with an alliance of Bristol Myers Squibb-Pfizer, as the CA-based manufacturer of wearable devices had been looking to take on rival Apple Inc.’s Apple Watch, a spokesman for Fitbit Inc.
had said in a statement late on Thursday, the 17th of October 2019. In point of fact, Fitbit Inc.’s latest attempt to partner up with healthcare Goliaths likes of Bristol Myers Squibb-Pfizer alliance comes over the heels of another tie-up that Fitbit Inc.
had stamped on August this year with the Government of Singapore to provide fitness trackers alongside others services under a health program which could help more than one million users. Apart from that, under the Thursday (October 17th) deal of Fitbit Inc., Fitbit Inc.’s devices would include software that would be able to track down irregular heart rhythms such as atrial fibrillation, the commonest type of irregularities in the heart rhythm that reveals an irregularly irregular hearth beat.
More importantly, an earlier detection of Atrial Fibrillation could help elderly people take preventive measures against critical diseases likes of Stroke, as AF (Atrial Fibrillation) alongside other irregular heart rhythms are closely associated with a number of cardiovascular diseases, while between 2.7 to 6 million people in the United States have been facing irregular heart rhythms, which usually remain mostly undetected before it comes to critical health conditions, data from US centre of Disease and Prevention revealed.